MX9707652A - Derivados de 1,3-dihidro-1-(fenilalquil)-2h-imidazol-2-ona y composiciones que los contienen usados com inhibidores de fosfodiesterasa iv y de citocina, y procedimiento para preparar dichos derivados. - Google Patents
Derivados de 1,3-dihidro-1-(fenilalquil)-2h-imidazol-2-ona y composiciones que los contienen usados com inhibidores de fosfodiesterasa iv y de citocina, y procedimiento para preparar dichos derivados.Info
- Publication number
- MX9707652A MX9707652A MX9707652A MX9707652A MX9707652A MX 9707652 A MX9707652 A MX 9707652A MX 9707652 A MX9707652 A MX 9707652A MX 9707652 A MX9707652 A MX 9707652A MX 9707652 A MX9707652 A MX 9707652A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- hydrogen
- 6alkyl
- formula
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion describe el uso de compuestos para la fabricacion de un medicamento para tratar animales de sangre caliente que sufren de estados de enfermedad relacionados con una actividad enzimática o catalítica anormal de fosfodiesterasa IV (PDE IV), y/o estados de enfermedad relacionados con exceso fisiologicamente dañino de citocinas, en particular enfermedades alérgicas, atopicas e inflamatorias, dichos compuestos tiene la formula (I), las formas de N-oxido, las sales de base ácidas de adicion farmacéuticamente aceptables y las formas estereoquímicamente isoméricas de los mismos, en donde R1 y R2 son cada uno independientemente hidrogeno; alquilo de C1-6, difluorometilo; trifluorometilo; cicloalquilo de C3-6; un heterociclo saturado de 5, 6 o 7 miembros que contiene uno o dos átomos heterogéneos seleccionados de oxígeno, azufre o nitrogeno; indanilo; biciclo[2.2.1]-2-heptenilo; biciclo[2.2.1]heptanilo; alquilsulfonilo de C1-6; arilsulfonilo; o alquilo de C1-10 substituid; R3 es hidrogeno, halo o alquiloxi de C1-6; R4 es hidrogeno; halo; alquilo de C1-6 substituido opcionalmente; trifluorometilo; cicloalquilo de C3-6; carboxilo; alquiloxicarbonilo de C1-4; cicloalquilaminocarbonilo de C3-6; arilo; Het1 o R4 es un radical de la formula: -O-R6; o -NH-R7; R5 es hidrogeno, halo, hidroxi o alquilo de C1-6; o R4 y R5 tomados juntos pueden formar un radical bivalente de la formula: -(CH2)n-; -CH2)-CH2-O-CH2-CH2-; -CH2-CH2-N(R8)-CH2-CH2-; o -CH2-CH=CH-CH2-; Y es una union directa haloalcanodiilo de C1-4 o alcanodiilo de C1-4; -A-B- es un radical bivalente de la formula: CR9=CR10-); o -CHR9-CHR10-; y L es hidrogeno, alquilo de C1-6 substituido opcionalmente; alquilcarbonilo de C1-6; alquiloxicarbonilo de C1-6; alquenilo de C3-6 substituido opcionalmente; piperidinilo substituido opcionalmente; alquilsulfonilo de C1-6 o arilsulfonilo; arilo es fenilo substituido opcionalmente; Het1 es morfolinilo o piridinilo substituido opcionalmente, -furanilo -tienil, -hidroxipiridinilo, -imidazolilo, -tiazolilo, -oxazolilo, -isoquinolinilo, -quinolinonilo, -piperidinilo o -piperazinilo; Het2 es morfolinilo o piperidinilo, -piperazinilo, -piridinilo, -furanilo, o -tienilo substituido opcionalmente; la presente invencion se refiere también a compuestos nuevos que tienen actividad inhibidora de PDE IV y citocina, a procedimientos para su preparacion y a composiciones que comprenden dichos compuestos nuevos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95200868 | 1995-04-06 | ||
| EP95202898 | 1995-10-26 | ||
| PCT/EP1996/001394 WO1996031485A1 (en) | 1995-04-06 | 1996-03-28 | 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives having pdeiv and cytokine activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9707652A true MX9707652A (es) | 1997-11-29 |
Family
ID=26139205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9707652A MX9707652A (es) | 1995-04-06 | 1996-03-28 | Derivados de 1,3-dihidro-1-(fenilalquil)-2h-imidazol-2-ona y composiciones que los contienen usados com inhibidores de fosfodiesterasa iv y de citocina, y procedimiento para preparar dichos derivados. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US5994376A (es) |
| EP (1) | EP0819122B1 (es) |
| JP (1) | JP4562101B2 (es) |
| KR (1) | KR100406628B1 (es) |
| CN (1) | CN1068591C (es) |
| AR (1) | AR002732A1 (es) |
| AT (1) | ATE214052T1 (es) |
| AU (1) | AU702947B2 (es) |
| CA (1) | CA2216653C (es) |
| CY (1) | CY2328B1 (es) |
| CZ (1) | CZ293127B6 (es) |
| DE (1) | DE69619661T2 (es) |
| DK (1) | DK0819122T3 (es) |
| ES (1) | ES2174064T3 (es) |
| HK (1) | HK1007880A1 (es) |
| HR (1) | HRP960155A2 (es) |
| HU (1) | HU223324B1 (es) |
| IL (1) | IL117807A (es) |
| MX (1) | MX9707652A (es) |
| MY (1) | MY119254A (es) |
| NO (1) | NO314339B1 (es) |
| NZ (1) | NZ304877A (es) |
| PL (1) | PL187375B1 (es) |
| PT (1) | PT819122E (es) |
| SI (1) | SI0819122T1 (es) |
| TW (1) | TW332201B (es) |
| WO (1) | WO1996031485A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| TW332201B (en) | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
| UA62939C2 (uk) * | 1996-10-02 | 2004-01-15 | Янссен Фармацевтика Н.В. | Похідне 2-ціаноіміноімідазолу, фармацевтична композиція та спосіб одержання сполуки |
| CN1261881A (zh) | 1997-07-10 | 2000-08-02 | 詹森药业有限公司 | 作为il－5－抑制剂的6－氮杂尿嘧啶衍生物 |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| SI1068194T1 (en) * | 1998-04-01 | 2004-04-30 | Janssen Pharmaceutica N.V. | Pde iv inhibiting pyridine derivatives |
| EP1071645A4 (en) * | 1998-04-14 | 2003-04-02 | Smithkline Beecham Corp | COMPOUNDS INHIBITING ISOENZYME PHOSPHODIESTERASE 4 (PDE 4) |
| US6172118B1 (en) * | 1998-04-14 | 2001-01-09 | Smithkline Beecham Corporation | Compounds |
| TR200101425T2 (tr) | 1998-11-23 | 2002-02-21 | Janssen Pharmaceutica N.V. | IL-5 inhibe edici 6-azaurasil türevleri |
| PL198205B1 (pl) | 1998-12-18 | 2008-06-30 | Janssen Pharmaceutica Nv | Inhibitująca IL-5 pochodna 6-azauracylu, jej zastosowanie i sposób wytwarzania, kompozycja farmaceutyczna, sposób znaczenia in vitro receptora i sposób obrazowania in vitro narządu |
| US6916810B2 (en) | 2000-09-13 | 2005-07-12 | Merck & Co., Inc. | αν integrin receptor antagonists |
| MXPA03010679A (es) | 2001-05-23 | 2004-03-02 | Tanabe Seiyaku Co | Una composicion para acelerar la cicatrizacion de fractura osea. |
| US20040180900A1 (en) | 2001-05-23 | 2004-09-16 | Masaharu Takigawa | Therapeutic composition for repairing chondropathy |
| US6706739B2 (en) * | 2001-08-21 | 2004-03-16 | National Health Research Institute | Imidazolidinone compounds |
| SE0200667D0 (sv) * | 2002-03-05 | 2002-03-05 | A & Science Invest Ab | Novel use of cytokine inhibitors |
| GB0326407D0 (en) * | 2003-11-12 | 2003-12-17 | Glaxo Group Ltd | Chemical compounds |
| GB0412865D0 (en) * | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
| US20080200526A1 (en) * | 2004-07-05 | 2008-08-21 | Jin Soo Lee | Composition for the Prevention and Treatment of Allergic Inflammatory Disease |
| AR057455A1 (es) * | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| WO2007085357A1 (en) * | 2006-01-30 | 2007-08-02 | Euro-Celtique S.A. | Cyclourea compounds as calcium channel blockers |
| EP1834953A1 (en) | 2006-03-14 | 2007-09-19 | Ranbaxy Laboratories Limited | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors |
| US7390772B2 (en) * | 2006-05-18 | 2008-06-24 | International Flavor & Fragrances Inc. | 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations |
| WO2008157425A2 (en) * | 2007-06-14 | 2008-12-24 | The Regents Of The University Of California | Compounds for inhibiting protein aggregation, and methods for making and using them |
| DK2544679T3 (da) | 2010-03-12 | 2019-07-22 | Omeros Corp | Pde10-inhibitorer og relaterede sammensætninger og fremgangsmåder |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| US9879002B2 (en) | 2015-04-24 | 2018-01-30 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL285394A (es) * | 1961-11-17 | |||
| US3184060A (en) | 1963-02-13 | 1965-05-18 | Owens Illinois Glass Co | Packaging tacky latex emulsion paints in containers manufactured from polyolefinic maerials |
| WO1992007567A1 (en) * | 1990-11-06 | 1992-05-14 | Smithkline Beecham Corporation | Imidazolidinone compounds |
| AU673569B2 (en) * | 1992-12-02 | 1996-11-14 | Pfizer Inc. | Catechol diethers as selective PDE-IV inhibitors |
| TW263495B (es) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| TW332201B (en) | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
-
1996
- 1996-03-22 TW TW085103447A patent/TW332201B/zh not_active IP Right Cessation
- 1996-03-28 DE DE69619661T patent/DE69619661T2/de not_active Expired - Lifetime
- 1996-03-28 AT AT96909150T patent/ATE214052T1/de active
- 1996-03-28 PL PL96322654A patent/PL187375B1/pl unknown
- 1996-03-28 HU HU9801575A patent/HU223324B1/hu active IP Right Grant
- 1996-03-28 DK DK96909150T patent/DK0819122T3/da active
- 1996-03-28 NZ NZ304877A patent/NZ304877A/en not_active IP Right Cessation
- 1996-03-28 PT PT96909150T patent/PT819122E/pt unknown
- 1996-03-28 EP EP96909150A patent/EP0819122B1/en not_active Expired - Lifetime
- 1996-03-28 ES ES96909150T patent/ES2174064T3/es not_active Expired - Lifetime
- 1996-03-28 MX MX9707652A patent/MX9707652A/es unknown
- 1996-03-28 CZ CZ19973149A patent/CZ293127B6/cs not_active IP Right Cessation
- 1996-03-28 US US08/930,296 patent/US5994376A/en not_active Expired - Lifetime
- 1996-03-28 CA CA002216653A patent/CA2216653C/en not_active Expired - Lifetime
- 1996-03-28 AU AU52755/96A patent/AU702947B2/en not_active Expired
- 1996-03-28 SI SI9630434T patent/SI0819122T1/xx unknown
- 1996-03-28 KR KR1019970706853A patent/KR100406628B1/ko not_active IP Right Cessation
- 1996-03-28 JP JP52995996A patent/JP4562101B2/ja not_active Expired - Lifetime
- 1996-03-28 CN CN96193101A patent/CN1068591C/zh not_active Expired - Lifetime
- 1996-03-28 WO PCT/EP1996/001394 patent/WO1996031485A1/en active IP Right Grant
- 1996-04-02 HR HR95202898.3A patent/HRP960155A2/hr not_active Application Discontinuation
- 1996-04-03 AR ARP960102076A patent/AR002732A1/es active IP Right Grant
- 1996-04-03 IL IL11780796A patent/IL117807A/en not_active IP Right Cessation
- 1996-04-05 MY MYPI96001300A patent/MY119254A/en unknown
-
1997
- 1997-10-06 NO NO19974602A patent/NO314339B1/no not_active IP Right Cessation
-
1998
- 1998-07-07 HK HK98108913A patent/HK1007880A1/xx not_active IP Right Cessation
-
1999
- 1999-07-27 US US09/362,007 patent/US6403805B1/en not_active Expired - Lifetime
-
2002
- 2002-07-15 CY CY0200043A patent/CY2328B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9707652A (es) | Derivados de 1,3-dihidro-1-(fenilalquil)-2h-imidazol-2-ona y composiciones que los contienen usados com inhibidores de fosfodiesterasa iv y de citocina, y procedimiento para preparar dichos derivados. | |
| HUP0102425A2 (hu) | Gyomorsav-elválasztást gátló imidazo-piridin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| AR012593A1 (es) | Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento | |
| YU59602A (sh) | Aril fuzionisana azapoliciklična jedinjenja | |
| YU27697A (sh) | Sulfonamidi i njihiova upotreba | |
| IE872650L (en) | Imidazopyridine derivatives, their production, and¹pharmaceutical compositions containing them | |
| MY119118A (en) | Thiophenopyrimidines | |
| NO884202D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazolin-2-okso-1-karboksylsyrederivater. | |
| MY129473A (en) | 3,3-diarylpropylamines, their use and preparation | |
| MY116980A (en) | Pde iv inhibiting 2-cyanoiminoimidazole derivatives | |
| NO173500C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzokon-densete N-holdige heterocykliske derivater | |
| ATE186301T1 (de) | An den positionen 2 und 9 substituierte 4h-pyrido-(1,2-a)pyrimidin-4-one | |
| HUP0001865A2 (hu) | Amino-pirimidin-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0003577A2 (hu) | Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| MY113446A (en) | 1,3-dihydro-1-(phenylalkenyl)-2h-imidazol-2-one derivatives | |
| TW375612B (en) | 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same | |
| MY124696A (en) | Pde iv inhibiting pyridine derivatives. | |
| CA2364719A1 (en) | 2-aminopyridines containing fused ring substituents | |
| NO971743D0 (no) | Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer | |
| ES8203875A1 (es) | Procedimiento para la preparacion de derivados de 2,3,4,5- tetrahidro-1-benzoxepin-3,5-diona | |
| IT1223395B (it) | Composti ad attivita' cardiovascolare | |
| US11466017B2 (en) | Heterocyclic inhibitors of PTPN11 | |
| NO176608C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperidinylindazol-derivater | |
| PL304334A1 (en) | Pharmaceutical composition of gastric protective action, including antiulceric one and method of treating diseases of gastrointestinal tract | |
| PT84005A (en) | 6h-isoxazol]3,4-d"pyrazolo]3,4-b"pyridines a process and intermediates for their preparation and their use as medicaments |